Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterised by ineffective haematopoiesis. According to the French-American-British (FAB) classification, MDS are subdivided in five groups including refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), refractory anemia with excess of blasts (RAEB), refractory anemia with excess of blasts in transformation (RAEB-t) and chronic myelomonocytic leukemia (CMML). MDS occur predominantly in elderly patients and evolve in acute myeloid leukemia (AML) in about 30% of the cases after variable intervals from diagnosis. 1 Recently, Lo Vasco et al 2 identified a cryptic deletion of band 20p12.3, involving the Inositide-specific phospholipase c b1 gene (PI-PLC b1), in MDS and AML patients with normal karyotypes. In their series, the deletion was frequent and observed in 33% (2/6) of AML cases and 44% (4/9) of MDS patients. Moreover, the deletion identified a MDS subgroup with normal karyotype and poor prognosis. Patients of this group were at high risk of developing AML with short survival periods (within 1-12 months after developing AML). Search for a deletion of the PI-PLC b1 gene appears thus to be of prognostic importance. However, the number of patients included in the series of Lo Vasco et al 2 was low (nine MDS and six AML patients) and, till now, no others studies have confirmed these findings.
In the present report, we assessed the frequency of PI-PLC b1 deletion in 23 MDS and seven AML patients with a normal karyotype at diagnosis (Table 1) . FISH investigations were performed with the same probe as in Lo Vasco's study, that is the PAC clone HS881E24 from P de Jong RPCI-5 PAC library. Our series included 17 men and 13 women, aged 25-96 years. The mean age of the MDS and AML populations was, respectively, of 71.9 and 52.2 years ( None of the 23 patients suffering from MDS nor the seven patients with AML had a deletion for the PI-PLC b1 locus when tested by FISH. These results are in contradiction with those of Lo Vasco et al 2 as they observed monoallelic deletion of the PI-PLC b1 gene in, respectively, 44 and 33% of the MDS and AML cases. The criteria of selection of our patients were, however, the same as those defined by Lo Vasco, that is, patients with AML or MDS and normal karyotypes at diagnosis. In the same way, the discrepancy between the two studies does not find its origin in the individual prognosis of the patients. In the series of Lo Vasco, six patients, of which four with MDS, had very short survival periods (inferior to 12 months) after diagnosis. All of them showed a deletion of the PI-PLC b1 locus. In our series, five patients developed AML. Three of them evolved rapidly and died within a period of 9-12 months after diagnosis (Table 1) . No deletion of the PI-PLC b1 gene was observed in these cases. However, the number of poor prognosis patients is low and does not allow definitive conclusions.
According to our results, systematic investigation of PI-PLC b1 deletions in SMD and AML patients with normal karyotypes is of limited interest. Indeed, PI-PLC b1 deletion appears to be a very rare event (even absent in our series), limiting thus its potential role in the discrimination of a high-risk SMD subgroup with normal karyotype as suggested by Lo Vasco et al. 2 Nevertheless, additional reports are needed to determine the exact frequency of PI-PLC b1 deletions in MDS patients. Myelodysplastic syndromes are characterized by leukemic progression in about a third of cases and the progression is a major cause of death. Evolution constitutes a major problem and the outcome is highly variable, especially in the low-and intermediate-risk categories, even though established with the refined International Prognostic Scoring System (IPSS), capable of a better predictivity with respect to the French-American-British (FAB) classification. In these cases, mostly normal or low-risk karyotypic changes are found. 1 The high-risk group often shows progression to acute myeloid leukemia (AML), being unresponsive to chemotherapy and AML is the cause of death, even though a number of patients do not progress to AML or are highly responsive to the treatment. The karyotype, carried out by GTG banding at diagnosis, could be normal, but cryptic rearrangements and deletion could change the risk status in some of the patients. 2 The analysis we previously reported 3 is based on a small number of patients (nine), with normal GTG banding karyotype and, as characterized by different meaning, that is FAB or IPSS, belonging to high-risk group. The patients' age was ranging from 58 to 77 years, and for different reasons, they were supplied only with supportive treatment. Four patients showed the monoallelic deletion of inositide-specific phospholipase C b1 (PI-PLCb1), whereas five did not. The latter patients at the time of the publication of the report were still alive, ranging the survival after diagnosis from 30 to 32 months. The four patients affected by the deletion died within 1-6 months after diagnosis from AML evolution.
Indeed, our data are strictly related to high-risk patients, as evaluated by clinical meanings, that is, FAB and IPSS, but bearing a normal karyotype, that from a cytogenetic point of view only, could be considered with favorable prognosis. We are keen to stress this point, even though in the Lo Vasco et al. paper, 3 the clinical features have not been fully explained. Even though the number of cases is small, we reckon that in this peculiar type of patients, the cryptic deletion of PI-PLCb1 gene is not a rare event. Therefore, in order to address this point as well as to further the understanding of the relationship between PI-PCLCb1 gene deletion and MDS/AML progression, we are currently evaluating a larger number of patients, coming from the Haematology Department of the University of Bologna, all with normal karyotype both at diagnosis and during disease progression, belonging to high risk, 13 patients (mean age 65 years), and low/intermediate risk, 10 patients (mean age 73 years), as established by IPSS and FAB as well. The rationale is based on the fact that the data reported by Lo Vasco et al.
3 might be of importance to identify a high-grade MDS/AML population, with a common pathophysiology owing to altered function of a key signalling intermediate in the control of cell cycle progression, that is, PI-PCLCb1. This also implies that the Lo Vasco et al. paper 3 is not aimed at all to change or challenge the value of the clinical parameters used for MDS classification, but is only aimed to give more insight into the intriguing and complex issue of MDS.
The FISH analysis carried out using the PI-PCLCb1 probe (PAC clone HS881E24 from P de Jong RPCI-5 PAC library) confirms that low-risk patients do not bear the deletion of PI-PCLCb1 gene and did not evolve to AML even in the absence of supportive care. On the contrary, four high-risk patients bear the deletion of PI-PCLCb1 gene, are unresponsive to MDS treatment and evolved to AML. The remaining nine high-risk patients do not show the deletion of PI-PCLCb1 gene and are responsive to MDS treatment.
Therefore, we reckon that a key point is the disclosure of specific classes of patients and that the identification of a highgrade MDS/AML population in patients bearing a normal GTG karyotype could be of importance in furthering the pathophysiology of MDS and of support for prognosis. In addition, this is also an answer to the Correspondence that appeared recently in Leukemia.
4 To achieve this goal, we are extending the analysis on this type of patients by collaborating with British centers in order to accumulate as much data as possible, but we do also ask other groups to enter the fray. In addition, in replying to Herens et al., 5 we add that we are keen to share our samples for further analysis. Moreover, it should be interesting to know also in the group of patients examined by Herens et al. how many of them belong to the high-risk group.
In conclusion, we do believe that a better and more comprehensive understanding of the alterations of signalling pathways in high-grade MDS/AML is necessary, given that these metabolic events are fundamental for the control of cell cycle progression. Interestingly, it has been very recently shown that frequent elevation of Akt kinase phosphorylation in bone marrow and peripheral blood mononuclear cells from high-risk MDS patients takes place, 6 and this could be related to an increase of phosphatidylinositol-bisphosphate, the substrate of both PI-PCLCb1 and of phosphatidylinositol 3-kinase, the enzyme that phosphorylates the Akt Kinase.
7 From a biological point of view, it could be that the increased availability of phosphatidylinositol-bisphosphate, owing to the monoallelic deletion of PI-PCLCb1 gene and partial loss of function of the PI-PCLCb1 itself in high-risk MDS patients, could pave the way for the well-known antiapoptotic pathway elicited by the phosphatidylinositol 3-kinase/Akt Kinase cascade, which in turn could increase the survival of MDS blasts in the bone marrow.
